ECA发布《GMP/GDP问答指南》V3.0 202609,摘录验证组工艺验证问答
ECA验证组精选问答——商业化前工艺验证不再拘泥于三批验证批次!
ECA发布《GMP/GDP问答指南》V3.0 202609,全文230页、含911个问答,本次摘录其中验证组的工艺验证问答。摘录的FDA问答说明,CGMP法规与FDA政策均未规定工艺验证所需的最少批次数量,验证不能简化为完成三批成功的全规模批次。其余问答比较持续工艺确认与连续工艺验证的定位,并收录FDA与EMA关于设计空间验证方案在申报资料3.2.R章节提交、加拿大卫生部对返工验证的答复。
2026年9月,,ECA发布了《GMP/GDP问答指南》V3.0 202609,全文230页,包含EU GMP 质量管理体系、共线生产、设备设施、生产管理、投诉及召回、无菌药品生产附录、计算机化系统、数据完整性等GMP正文及各附录、FDA cGMP、ICH、ECA 可见异物检查、ECA 数据完整性等911个问题解答,以下为ECA验证组精选问答。
1.What are the differences between Continued and Continuous Process Verification ? How fits Ongoing Process Verification in between?
持续工艺确认与连续工艺验证有何区别?持续工艺验证在二者中处于何种定位?
Continuous Process Verification is defined in the ICH Q 8 glossary: An alternative approach to process validation in which manufacturing process performance is continuously monitored and evaluated. The basis for Continuous Process Verification is a Quality by Design development. Process Analytical Technologies are enablers for a Continuous Process Verification approach in manufacturing. See also FDA´s Q&A Paper.
ICH Q8 术语表对连续工艺验证的定义:是工艺验证的替代方法,持续对生产工艺性能进行监控与评估。连续工艺验证基于质量源于设计的研发思路。过程分析技术是在生产中实施连续工艺验证方法的支撑手段。另参见 FDA 问答文件。
Continued Process Verification is stage 3 of FDA´s Process Validation Life Cycle. It is in the glossary of FDA Process Validation Guidance described: Assuring that during routine production the process remains in a state of control.
持续工艺确认是 FDA 工艺验证生命周期的第 3 阶段。FDA 工艺验证指南术语表定义:确保常规生产期间工艺始终处于受控状态。
In the glossary of the revised Annex 15 is Ongoing Process Verification defined: Ongoing Process Verification (also known as continued process verification) - Documented evidence that the process remains in a state of control during commercial manufacture.
修订后的附录 15 术语表定义了持续工艺验证:持续工艺验证(也称为持续工艺确认)—— 证明商业化生产阶段工艺持续处于受控状态的文件化证据。
So Continued and ongoing process verification have the same goal. But in the FDA Guidance there is more emphasis on statistics regarding Continued Process Verification than in the revised Annex 15. For instance, the FDA Guidance requires: We recommend that a statistician or person with adequate training in statistical process control techniques develop the data collection plan and statistical methods and procedures used in measuring and evaluating process stability and process capability. And the FDA guidance recommends sampling of process parameters and quality attributes at the level established during the process qualification stage until sufficient data are available to generate significant variability estimates.
因此持续工艺确认与持续工艺验证目标一致。但相较于修订版附录 15,FDA 指南针对持续工艺确认更强调统计学应用。例如,FDA 指南要求:建议由统计师或受过统计过程控制技术充分培训的人员,制定数据采集方案以及用于测量和评估工艺稳定性与工艺能力的统计方法和规程。FDA 指南还建议,在获取足够数据以得到可靠的变异性估计之前,按照工艺确认阶段确定的水平对工艺参数与质量属性进行取样。
You will find a lot of possible questions are answered in the Presentations section.
演示文稿板块解答了很多相关问题。
The following questions and answers are included in the GMP Question and Answer Guide „GMP Advisor“.
以下问答收录于 GMP 问答指南《GMP Advisor》。
2.FDA:Do CGMPs require three successful process validation batches before a new active pharmaceutical ingredient (API) or a finished drug product is released for distribution?
FDA: CGMP 是否要求新原料药(API)或制剂放行上市前完成三批成功的工艺验证批次?
No. Neither the CGMP regulations nor FDA policy specifies a minimum number of batches to validate a manufacturing process. The current industry guidance on APIs (see ICH Q7A for APIs) also does not specify a specific number of batches for process validation. The GMP Questions & Answers Guide Version 1.0 Page 55 of 152
不要求。CGMP 法规与 FDA 政策均未规定生产工艺验证所需的最少批次数量。现行原料药行业指南(参见原料药 ICH Q7A)同样未指定工艺验证的具体批次。GMP 问答指南 1.0 版,第 55 页(共 152 页)
FDA recognizes that validating a manufacturing process, or a change to a process, cannot be reduced to so simplistic a formula as the completion of three successful full scale batches. The agency acknowledges that the idea of three validation batches has become prevalent, in part due to language in its own guidance documents. However, FDA is now clarifying current expectations on process validation. The Guideline of General Principles of Process Validation is currently being revised to address this issue. The emphasis for demonstrating validated processes is placed on the manufacturer’s process design and development studies in addition to its demonstration of reproducibility at scale, a goal that has always been expected.
FDA 认为,生产工艺验证或工艺变更验证,不能简单等同于完成三批成功的全规模批次。FDA 承认三批验证的理念广为流传,部分原因源自其自身指南文件表述。但 FDA 目前正在澄清现行工艺验证要求。《工艺验证通用原则指南》正在修订以解决该问题。验证工艺的证明重点,除规模化重现性证明外,还需关注生产商的工艺设计与研发研究,这也是一直以来的预期目标。
However, a minimum number of conformance (a.k.a. validation) batches necessary to validate the manufacturing processes is not specified. The manufacturer is expected to have a sound rationale for its choices in this regard. The agency encourages the use of science based approaches to process validation.
但法规并未规定生产工艺验证所需的最少符合性批次(又称验证批次)数量。生产商需对此选择提供充分合理依据。FDA 鼓励采用基于科学的工艺验证方法。
In March 2004, FDA revised the Compliance Policy Guide (CPG) (Sec. 490.100) on Process Validation Requirements for Drug Products and Active Pharmaceutical Ingredients Subject to Pre-Market Approval .The CPG describes the concept that, after having identified and establishing control of all critical sources of variability, conformance batches are prepared to demonstrate that under normal conditions and operating parameters, the process results in the production of acceptable product. Successful completion of the initial conformance batches would normally be expected before commercial distribution begins, but some possible exceptions are described in the CPG. For example, although the CPG does not specifically mention concurrent validation for an API in short supply, the agency would consider the use of concurrent validation when it is necessary to address a true short-supply situation, and if the concurrent validation study conforms to the conditions identified in the CPG (See paragraph 4. a-c).
2004 年 3 月,FDA 修订《合规政策指南》(CPG,490.100 章节),主题为需上市前批准的制剂与原料药工艺验证要求。该 CPG 阐述:在识别所有关键变异来源并建立控制之后,开展符合性批次生产,证明在常规条件与操作参数下,该工艺能够产出合格产品。通常要求在商业化分销前完成初始符合性批次;CPG 中描述了若干例外情形。例如,虽然 CPG 未专门提及短缺原料药的同步验证,但当确实存在供应短缺、且同步验证研究满足 CPG 所列条件时,FDA 可考虑采用同步验证(参见 4.a-c 段)。
The conditions outlined in the CPG include expanded testing for each batch intended to address a short-supply situation. Expanded testing, conducted according to an established validation protocol could provide added assurance that the batch meets all established and appropriate criteria before the API is used in the finished drug product. Additionally, confidence in the API manufacturing process may be gained by enhanced sampling (larger sample size representative of batch) and perhaps the testing of additional attributes. Validated analytical methods are needed for testing every batch, including validation batches. The agency would also expect the manufacturer to use a validation protocol which includes a review and final report after multiple batches are completed, even though the earlier batches may have been distributed or used in the finished drug product.
CPG 列明的条件包括:针对供应短缺场景下的每一批次开展扩展检验。按照既定验证方案实施扩展检验,可在原料药用于制剂生产前,额外保证该批次满足所有既定的适用标准。此外,可通过增强取样(更大、具备批次代表性的样本量)以及额外质量属性检验,增加对原料药生产工艺的信心。所有批次(含验证批次)的检验均需使用经过验证的分析方法。FDA 还要求生产商使用验证方案,方案要求在多批次完成后开展审核并出具最终报告,即便前面的批次已经分销或投入制剂生产。
3.FDA recently announced the withdrawal of its draft guidance for industry on Powder Blends and Finished Dosage Units — Stratified In-Process Dosage Unit Sampling and Assessment. What were the Agency’s major concerns with this guidance?
FDA 近期宣布撤回行业指南草案《粉末混合物与成品制剂单元 —— 分层中间制剂取样与评估》。FDA 对这份指南草案的主要顾虑是什么?
FDA’s major concern was that Sections V and VII of the withdrawn draft guidance no longer represented the Agency’s current thinking, as explained below.
FDA 主要顾虑:被撤回指南草案的第 V 章与第 VII 章已不再代表 FDA 当前观点,详述如下。
Section V (Exhibit/Validation Batch Powder Mix Homogeneity) recommended that at least three replicate samples be taken from at least ten locations in the powder blender, but that only one of the three replicates be evaluated to assess powder blend uniformity. The Agency currently recommends that all replicate samples taken from various locations in the blender be evaluated to perform a statistically valid analysis. This analysis can demonstrate that variability attributable to sample location is not significant and that the powder blend is homogenous. Statistical tools are available to ascertain both the number of replicates and the number of sampling locations across the blender that should be analyzed to conduct a valid analysis.
第 V 章(验证批次粉末混合均匀性)曾建议,在粉末混合机至少 10 个点位采集至少 3 份平行样,但仅检测 3 份平行样中的 1 份来评估粉末混合均匀度。FDA 当前建议:对混合机不同点位采集的全部平行样品均进行检测,以完成具备统计学有效性的分析。该分析可证明由取样位置带来的变异性不显著,粉末混合物均匀。可借助统计工具确定有效分析所需的平行样数量、混合机取样点位数量。
Section VII (Routine Manufacturing Batch Testing Methods) acceptance criteria designated to the Standard Criteria Method and the Marginal Criteria Method were based upon the limits published in the United States Pharmacopeia (USP) General Chapter <905> Uniformity of Dosage Units. However, the procedures and acceptance criteria in USP <905> are not a statistical sampling plan and so the results of the procedures should not be extrapolated to larger populations. Therefore, because the procedure and acceptance criteria prescribed in section VII provided only limited statistical assurance that batches of drug products met appropriate specifications and statistical quality control criteria, FDA no longer supports their use for batch release. Currently, there are several standard statistical practices (see references) that, if used correctly, can help to ensure compliance with the current good manufacturing practice (CGMP) regulations, including 21 CFR 211.110 Sampling and testing of inprocess materials and drug products, 21 CFR 211.160 General Requirements [Subpart I, Laboratory Controls],and 21 CFR 211.165 Testing and release [of the finished drug product] for distribution.
第 VII 章(常规生产批次检验方法)针对标准判定法与临界判定法设定的可接受标准,基于美国药典通则 < 905 > 制剂均一性的限度。但 USP<905 > 中的规程与可接受标准不属于统计取样方案,其结果不可外推至更大总体。因此,第 VII 章规定的规程与可接受标准,仅能提供有限统计学保障,无法保证制剂批次满足合适的质量标准与统计质控要求,FDA 不再支持将其用于批次放行。目前有若干标准统计方法(参见参考文献),正确使用可确保符合现行药品生产质量管理规范(CGMP)法规,包括 21 CFR 211.110 中间物料与制剂取样检验、21 CFR 211.160 通用要求(I 分篇,实验室控制)以及 21 CFR 211.165 成品检验与上市放行。
4. Why is FDA concerned about proper sampling of powder blends?
FDA 为何关注粉末混合物的规范取样?
The CGMPs require that all sampling plans be scientifically sound and representative of the batch under test (see 211.160 (b)). Further, in-process testing of powder blends to demonstrate adequacy of mixing is a CGMP requirement (21 CFR 211.110). Between- and within-location variability in the powder blend is a critical component of finished product quality and therefore should be evaluated. Drug product manufacturers need to use a science- and risk-based sampling approach to assure (a) adequacy of blend mixing and (b) that sampling of the blend is done at a suitable juncture in the manufacturing process. The sampling and analysis needs to ensure that no differences exist between locations in a blend that could adversely affect finished product quality. Traditional sampling using a powder thief may have drawbacks and limitations, such as causing disturbance to the powder bed, powder segregation, or other sampling errors. However, powder-thief sampling remains widely used and provides reliable results in many cases. The Agency encourages firms to adopt more innovative approaches to ensuring adequacy of mixing (see, e.g., the PAT guidance). If a manufacturer proposes to use a thief sampling method, the reliability of the method should be evaluated as part of analytical methods development.
CGMP 要求所有取样方案具备科学合理性,且能够代表被检批次(参见 211.160 (b))。此外,对粉末混合物开展中间检验以证明混合充分性属于 CGMP 强制要求(21 CFR 211.110)。粉末混合物的点位间与点位内变异性是成品质量关键要素,因此必须评估。制剂生产商需采用基于科学与风险的取样方法,确保(a)混合充分;(b)在生产工艺合适节点开展混合物取样。取样与分析工作需保证混合物内部不存在会对成品质量产生不良影响的点位差异。传统粉末取样器取样存在缺陷与局限性,例如扰动粉体层、引发粉末分层或其他取样误差。但粉末取样器取样目前仍广泛使用,多数场景下结果可靠。FDA 鼓励企业采用更创新的方法保证混合充分性(例如 PAT 指南)。若生产商计划采用取样器取样法,需将该方法的可靠性评估纳入分析方法开发工作。
5.What are some recommended innovative approaches to ensuring adequacy of mixing of powder blends?
有哪些推荐的创新方法,可用于保证粉末混合物混合充分?
Innovative approaches to consider include, but are not limited to: (a) Process Analytical Technology (PAT) real-time monitoring and feedforward controlling of the powder blending process and (b) use of Statistical Process Control (SPC) tools to monitor the powder blending process and to maintain a state of control.
可考虑的创新方法包括但不限于:(a) 采用过程分析技术(PAT)对粉末混合工艺实施实时监控与前馈控制;(b) 使用统计过程控制(SPC)工具监控粉末混合工艺,维持受控状态。
When a manufacturer decides to implement PAT or other process-monitoring and control techniques for powder blend homogeneity assessment, its decision should be supported with appropriate data and rationale using a science- and risk-based approach. For example, the effective sample size of powder examined by PAT probes has to be estimated, such that the scale of scrutiny of the PAT powder blending monitoring can be justified. The number of PAT probes and their locations also have to be justified. If a scientifically sound PAT monitoring and control strategy is established, it can facilitate the assessment of: (a) variability across locations within the powder bed, (b) the variability over time of one location, and (c) the potential correlation between the powder sample and the unit dosage form.
当生产商决定采用 PAT 或其他工艺监控控制技术评估粉末混合均匀度时,该决策需依托基于科学与风险思路的合适数据与理由支撑。例如,必须估算 PAT 探头检测粉末的有效样本量,以此论证 PAT 粉末混合监控的检查尺度合理。PAT 探头数量与安装位置同样需要论证。若建立科学可靠的 PAT 监控与控制策略,则有助于评估:(a) 粉体层内部不同点位之间的变异性;(b) 单个点位随时间产生的变异性;(c) 粉末样品与制剂单元之间潜在的相关性。
6.What are the Agency’s recommendations regarding in-process stratified sampling of finished dosage units?
FDA 针对成品制剂单元的中间分层取样有哪些建议?
Stratified sampling is recommended to be used when the population is known to have several subdivisions (i.e., locations) which may give different results for the quality characteristics measured. The Agency expects that no significant differences should exist between in-process locations that could affect finished product quality. Between- and within- location variability is a critical component of finished product quality and therefore should be evaluated. Please refer to ASTM E2709 and ASTM E2810 for further guidance on establishing acceptance criteria for a stratified sampling plan.
当已知总体包含多个子分区(即不同点位),且这些点位测得的质量特性结果可能存在差异时,推荐采用分层取样。FDA 要求:中间取样点位之间不得存在会影响成品质量的显著差异。点位间与点位内变异性是成品质量的关键组成部分,因此必须评估。关于分层取样方案可接受标准制定的更多指导,请参见 ASTM E2709 与 ASTM E2810。
7.Health Canada: Q.10: It is generally accepted in the industry to perform process validation on three consecutive lots. How does the Inspectorate view validation when reworking is required (i.e., three consecutive incidents will never happen)?
加拿大卫生部:行业普遍采用连续三批开展工艺验证。当需要返工(也就是无法获得连续三批合格批次)时,核查机构如何看待验证工作?
A.Reworking of a batch should be a very rare occurrence. As such, validation of reworking is not considered mandatory as it is not generally feasible. The reworking should be carried out in accordance with a defined procedure approved by Quality Control (QC) and with the conditions described in Interpretation 6 of Section C.02.014 Quality Control Department. This procedure should include supplementary measures and testing during the reworking operations to ensure that the quality of the final product is not compromised.
答:批次返工应当属于极少见情况。因此返工验证不强制要求,因为通常不具备可行性。返工必须按照经质量控制部门(QC)批准的既定规程执行,并遵守 C.02.014 章节(质量控制部)释义 6 描述的条件。规程中应包含返工过程中的补充措施与检验项目,确保成品质量不受损害。
It is mandatory that rework proposals and reworked product also be fully investigated with respect to impact on release characteristics and potential impact on bio-availability. Changes in formulation due to reworks including the incorporation of additional lubricant or dissolution aid or additional critical processes may require comparative bio-availability studies. Furthermore concomitant stability studies must be undertaken on reworked batches to ensure that critical characteristics are not compromised with time due to the rework.
必须对返工方案与返工产品开展全面调查,评估其对放行指标的影响以及对生物利用度的潜在影响。返工引发的处方变更(例如额外加入润滑剂、助溶剂或增加关键工艺步骤),可能需要开展对比生物利用度研究。此外,必须对返工批次同步开展稳定性研究,确保产品关键特性不会因返工而随时间发生劣化。
8.ICH: What is an appropriate approach for process validation using ICH Q8, Q9, and Q10?
ICH:结合 ICH Q8、Q9、Q10,合适的工艺验证思路是什么?
A: The objectives of process validation are unchanged when using ICH Q8, Q9, and Q10. The main objective of process validation remains that a process design yields a product meeting its predefined quality criteria. ICH Q8, Q9, and Q10 provide a structured way to define product critical quality attributes, design space, the manufacturing process, and the control strategy. This information can be used to identify the type and focus of studies to be performed prior to and on initial commercial production batches. As an alternative to the traditional process validation, continuous process verification (see definition in ICH Q8 (R2) glossary) can be utilized in process validation protocols for the initial commercial production and for manufacturing process changes for the continual improvement throughout the remainder of the product lifecycle.
答 :采用 ICH Q8、Q9、Q10 框架时,工艺验证目标保持不变。工艺验证的核心目标依旧是证明工艺设计可以产出满足预设质量标准的产品。ICH Q8、Q9、Q10 提供结构化方法,用于定义产品关键质量属性、设计空间、生产工艺以及控制策略。可依托上述信息确定在商业化首批生产之前及首批商业化批次上需要开展研究的类型与重点。作为传统工艺验证的替代方案,可在商业化首批生产、以及产品生命周期剩余阶段用于持续改进的生产工艺变更的工艺验证方案中采用连续工艺验证(参见 ICH Q8 (R2) 术语表定义)。
9.ICH: How can information from risk management and continuous process verification provide for a robust continual improvement approach under ICH Q8, Q9 and Q10?
ICH:依据 ICH Q8、Q9、Q10,风险管理与连续工艺验证产生的信息,如何支撑稳健的持续改进方法?
A: Like the product itself, process validation also has a lifecycle (process design, process qualification and ongoing process verification). A risk assessment conducted prior to initial commercial validation batches can highlight the areas where particular focus and data collection could demonstrate the desired high level of assurance of commercial process robustness. Continual monitoring (e.g., via continuous process verification) can further demonstrate the actual level of assurance of process consistency and provide the basis for continual improvement of the product. Quality Risk Management methodologies of ICH Q9 can be applied throughout the product lifecycle to maintain a state of process control. (Approved October 2009)
答 :与产品本身一样,工艺验证同样具备生命周期(工艺设计、工艺确认以及持续工艺验证)。在商业化首批验证批次生产前开展风险评估,可识别需要重点关注与数据采集的领域,以此证明商业化工艺稳健性达到预期的高保障水平。持续监控(例如通过连续工艺验证)可进一步证明工艺一致性的实际保障水平,并为产品持续改进提供依据。ICH Q9 的质量风险管理方法可在整个产品生命周期内应用,维持工艺受控状态。
10.ICH Q9: Should the outer limits of the design space be evaluated during process validation studies at the commercial scale?
ICH Q9:问题:商业化规模的工艺验证研究中,是否需要评估设计空间的边界极限?
A: No. There is no need to run the qualification batches at the outer limits of the design space during process validation studies at commercial scale. The design space should be sufficiently explored earlier during development studies (for scale-up, see also section II.B.1 Design Space (2.1), Q2; for lifecycle approach, see section II.A For General Clarification (1.1), Q3). (Approved November 2010)
答 :不需要。商业化规模工艺验证研究期间,无需在设计空间的边界极限条件下开展确认批次生产。设计空间应在前期研发研究中完成充分探索(放大相关内容参见 II.B.1 章节 设计空间 (2.1),Q2;生命周期方法参见 II.A 章节 通用说明 (1.1),Q3)。
11.FDA and EMA . How should design space verification protocol be addressed in the submission?
FDA 与 EMA. 申报资料中应当如何阐述设计空间验证方案?
In principle, a design space verification protocol could include the following: list of scale dependent parameters whose impact on the CQAs has not been verified at commercial scale, definition of the potential scale-up risks to the CQAs, discussion of whether the control strategy can address these risks, and description of any additional controls, as needed. EU authorities' expectation is that a protocol for design space verification be submitted in section 3.2.R of the application. At the time of submission, a proposed design space not verified at commercial scale should be accompanied by an appropriate verification protocol. The protocol would be assessed at the time of review. Verification data are managed and documented in the site change management system.
原则上,设计空间验证方案可包含以下内容:对关键质量属性(CQA)的影响尚未在商业化规模下验证的规模相关参数清单、对关键质量属性存在的潜在放大风险定义、讨论控制策略是否能够应对上述风险,以及根据需要描述额外的控制措施。欧盟监管机构要求,设计空间验证方案应在申报资料 3.2.R 章节提交。申报时,若拟定的设计空间尚未在商业化规模完成验证,则需配套提交合适的验证方案。该方案将在审评阶段接受评估。验证数据在厂区变更管理系统中进行管理与记录。
FDA's expectation is that any plans for design space verification be available at the manufacturing site as an element of the change control, validation, and/or knowledge management strategy. Providing data for initial design space verification and a high-level overview of the plan for design space verification over the product lifecycle can be beneficial to the review of the application.
FDA 的要求:设计空间验证的相关计划应在生产现场留存,作为变更控制、验证和 / 或知识管理策略的组成部分。提交初始设计空间验证数据以及产品全生命周期设计空间验证计划的概述,有助于申报资料的审评。
12.FDA and EMA Q8. What is the difference between process validation and design space verification?
FDA 与 EMA:工艺验证和设计空间验证的区别是什么?
Design space verification should not be confused with process validation. Both take into consideration prior knowledge and development conclusions and are conducted at commercial scale, however the scope of the studies are not the same. Whereas process validation demonstrates consistency of the process at normal operating ranges, design space verification demonstrates that scale effect and or model assumptions are under control in the new area of design space and do not affect product quality. Unlike validation which covers all the steps of the manufacturing process, verification studies refer only to those operations where a design space has been proposed. In order to address the risks identified during the risk assessment of operating in the unverified area of the design space the verification studies may also include additional testing /monitoring of additional parameters or at an increased frequency as compared to the routine control strategy. When verification data proves that the extent of movement within the design space is of high risk (e.g. critical quality attributes are met but close to edge of failure identified at laboratory/pilot scale), process validation (consistency of the process) in the new area of design space (new NOR) should also be considered. A protocol for design space verification should be submitted in section 3.2.R. irrespective of the validation approach. When a strategy for continuous verification is envisaged, where relevant, the elements of design space verification should be included as part of the continuous verification protocol. It is understood that when an applicant can demonstrate that the design space is scale independent then a verification protocol is not requested in the dossier. NB: Continuous Process Verification is an alternative approach to traditional process validation in which manufacturing process performance is continuously monitored and evaluated (ICH Q8).
不可将设计空间验证与工艺验证混淆。二者均需结合前期知识与研发结论,并在商业化规模开展,但研究范围不同。工艺验证证明工艺在正常操作范围内的一致性;而设计空间验证证明,在设计空间新区域内,规模效应和 / 或模型假设处于受控状态,且不会影响产品质量。工艺验证覆盖生产工艺全部步骤,而验证研究仅针对拟定了设计空间的相关操作。为应对在设计空间未经验证区域内生产所识别的风险,相较于常规控制策略,验证研究可能增加额外参数的检验 / 监控项目,或提高取样检测频率。若验证数据证明,在设计空间内的变动属于高风险(例如:关键质量属性虽合格,但已接近实验室 / 中试规模确定的失效边界),则还应考虑在设计空间新区域(新的正常操作范围 NOR)开展工艺验证(工艺一致性验证)。无论采用何种验证方法,设计空间验证方案均应在 3.2.R 章节提交。若计划采用连续验证策略,在相关情况下,设计空间验证要素应纳入连续验证方案。如申报人能够证明设计空间与规模无关,则申报资料中无需提交验证方案。注:连续工艺验证是传统工艺验证的替代方法,对生产工艺性能进行持续监控与评估(ICH Q8)。
13.EMA: Manufacture of the medicinal products - Process control
EMA:药品生产 - 工艺控制
When validating a manufacturing process, if a common bulk is used to manufacture a series of products, how should the pilot batch size be decided upon? H+V
在工艺验证时,若使用同一中间料生产一系列产品,中试批次规模应如何确定?人用 + 兽用
It is the applicant's responsibility to select and justify the pilot batch size.
由申报人负责选择中试批次规模并提供论证依据。
The Joint Committee for Medicinal Products for Human Use and Committee for Medicinal Products for Veterinary Use guideline on process validation (CPMP/QWP/848/96, CVMP/598/99) states that, “pilotbatch size should correspond to at least 10% of the future industrial scale batch i.e. such that the multiplication factor for scale-up does not exceed 10. For oral solid dosage forms this size should be at least 10% or 100,000 units whichever is greater* unless otherwise justified”.
人用药品委员会与兽用药品委员会联合发布的工艺验证指南(CPMP/QWP/848/96,CVMP/598/99)规定:“中试批次规模至少为未来工业化生产批次的 10%,即放大倍数不超过 10 倍。对于口服固体制剂,该规模至少为工业化批量的 10% 或 100,000 制剂单位,取二者中较大值 *,另有充分论证的情况除外。”
The guideline does not dictate that the 10% figure should always be linked to the scale of manufacture of individual product presentations. In addition, it allows for departures from the guidance where this is justified. Furthermore, the guideline does not preclude the use of bracketing. Certain bulk products are used to produce a series of presentations, for example a bulk powder blend may be used to produce 50-mg, 100-mg and 200-mg direct compression tablets with the same percentage composition. In such instances, as long as the applicant can demonstrate a satisfactory link between the pilot batch size used for validation and the routine production batch size, it will usually be acceptable to define the pilot batch size as 10% of the planned production scale for the bulk product. During the process validation study, the complete pilot scale bulk batch should be used to manufacture the individual presentations. The division of the bulk batch between the different presentations should also be justified.
该指南并未强制要求 10% 的比例必须对应单个成品规格的生产规模。此外,如具备充分理由,允许偏离该指南要求。同时,指南不禁止采用括号法。部分中间物料用于生产多个成品规格,例如同一粉末混合物中间料可生产 50mg、100mg、200mg 相同组分占比的直接压片片剂。在这种情况下,只要申报人能够证明验证所用中试批次规模与常规生产批次规模具备合理关联性,通常可将中试批次规模定为中间物料计划生产规模的 10%。在工艺验证研究中,需使用完整中试规模的中间料批次生产各个成品规格。将中间料批次拆分用于不同成品规格的方案也需要论证。
*In the case of veterinary medicinal products, the minimum pilot size may be smaller than 100,000 units where justified.
* 对于兽用药品,如具备充分论证,中试最小规模可低于 100000 制剂单位。
来源:制药经理人 · mp.weixin.qq.com